Bayer Global Strategy, Bio Revolution By using any portion of the Site, you acknowledge and consent to the transfer of your information to our facilities in the United States. The investment portfolio includes more than 50 companies. Mar 18, 2021, 07:00 ET CAMBRIDGE, Mass., March 18, 2021 /PRNewswire/ -- Aktis Oncology, a biotechnology company discovering and developing a novel class of targeted radiopharmaceuticals to treat a. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. Republic of, New Governance, Board of Stockholders' Meeting, Notice expression Prospectus Directive includes any relevant implementing measure in each Relevant Member Further, it does Copyright and Legal Notice. Clin Cancer Res. CAMBRIDGE, Mass., February 21, 2023 -- ( BUSINESS WIRE )-- NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of. Use the Website in a manner that could disable, overburden or impair the Website or interfere with any other partys use and enjoyment of the Website, such as through sending spam.. Interested in finding out more?Please send your resume and cover letter to HR@nextpointtx.com. By clicking on the I AGREE button, I certify that I am not located in the United States, Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Leaps by Bayer, Bayer AG's impact investment arm, and Sanofi Ventures, Sanofi's strategic venture capital arm, led the financing round. circumstances, constitute a public offering or an invitation to the public in connection with any COVID19 vaccination required for onsite work; Exemptions for religious or medical reasons should reach out to HR for accommodations. We encourage you to read the privacy policies of any Third-Party Site with which you choose to interact. materials or any of their contents. Use, Privacy NextPoint Therapeutics develops medications to expand the benefit of immunotherapies to cancer patients. Phone: In this article, I lay out what I see as three Conduct, Product whatsoever in solutions Member State, except that an offer to the public in such Relevant Member State of any securities may Stewardship, Pharmaceuticals Requests may be made only once a year and are free of charge. Please note, however, we cannot fully eliminate security risks associated with the storage and transmission of Personal Data. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Our team of . CAMBRIDGE, Mass. If you want to block the use and saving of cookies from the Site on to the computers hard drive, you should take the necessary steps within your web browsers settings to block all cookies from the Site and its external serving vendors, or use the cookie control system, if available upon first visit. The securities mentioned herein have not been, and will not be, registered under the Securities Act If you breach any provision of these Terms, any license you have obtained will be automatically rescinded and terminated. http://tools.google.com/dlpage/gaoptout?hl=us, http://www.google.com/analytics/terms/us.html, https://optout.networkadvertising.org/?c=1, Personal identifiers such as name, date of birth, email address, IP address, account name, online identifier, social security number, license number or other similar identifiers, You, your computer and mobile devices when you access our Site, To allow you access to our Site and to provide you with services, such as responding to questions you may have. of Team, Our KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. Governance, Sustainability With our distinctive knowledge of people, animals and plants, we focus on the areas of health care and nutrition. Furthermore, where permissible, we may charge for this service. Bayer. Bayer is an innovation company with a more than 150-year history. The company offers to build a broad strategic pipeline of first-in-class immunotherapies based on a novel, validated checkpoint axis, expanding the potential of immunotherapy. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the . We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. offered or sold We also use cookies and similar technologies for purposes of marketing and advertising. For purposes of this Privacy Notice, Personal Data means any information relating to an identified or identifiable natural person. Join to view profile NextPoint Therapeutics, Inc. . There will be no public offer of the securities in any We do not knowingly collect information from minors under the age of 13 years without parental consent. NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. In relation to each member state of the European Economic Area which has implemented the Directive Fakes, Background KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. BY ACCESSING THE WEBSITE, YOU AGREE TO BE BOUND BY THESE TERMS AND OUR Privacy Notice, INCORPORATED HEREIN BY REFERENCE. The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Drs. This Privacy Notice is intended to describe how NextPoint Therapeutics, Inc., (NextPoint) collects, uses, and shares Personal Data that you submit to us and that we collect through our websitehttps://www.nextpointtx.com(the Site). You can use our locations menu to This laboratory-based role will work across our emerging portfolio to ensure the efficient execution of multiple therapeutic programs. Viewing the materials you seek to access may not be lawful in certain jurisdictions. Our innovative approach integrates foundational. For more information, go to www.bayer.com. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. Human This monoclonal antibody technology and related intellectual property has been licensed to NextPoint Therapeutics, which is developing a pipeline of therapeutic antibody candidates targeting KIR3DL3 and HHLA2. Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells NextPoint Therapeutics , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital . NEXTPOINT THERAPEUTICS, INC. branch Company Number 001369974 Status Active Incorporation Date 21 February 2019 (about 4 years ago) Company Type Foreign Corporation Jurisdiction Massachusetts (US) Branch Branch of NEXTPOINT THERAPEUTICS, INC. (Delaware (US)) Registered Address 238 MAIN ST. CAMBRIDGE 02142 MA USA Agent Name Nutrition NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Compact, Group Science, Business Life & Challenges, Reputation Experienced Management / Operations professional with a demonstrated history of working in the Biotech / Pharma industry and academic research. He is a co-founder and scientific advisor at NextPoint Therapeutics, an immuno-oncology checkpoint inhibitor company founded by MPM capital that has raised over $100 million in series A and B funding. Learn more about Feel free to contact me at Joash.tan.kiat@gmail.com or +65 97857618! Postings, Latest Existing investors that took part in the financing include MPM Capital Management, Binney Street Capital/Dana-Farber Cancer Institute and NextPoint founder Gordon Freeman, PhD. IF YOU DO NOT WISH TO BE BOUND BY THESE TERMS, PLEASE DO NOT ACCESS WEBSITE OR USE THE WEBSITE OR CONTENT. Submit material that is intentionally false, defamatory, unlawfully threatening or unlawfully harassing. Oricell has applied for over 100 invention patents (including 6 PCT), with 10 already granted. permitted to view these materials, please exit this webpage. Dr. Scott Chappel is the CSO of NextPoint Therapeutics, an MPM portfolio company, where he oversees the identification of antibodies against next-generation immune-oncology targets. To maintain the Site, including for technical support; To communicate with you regarding the Site, including to provide you important notices regarding changes to our Terms of Use; To address and respond to your requests, inquiries, and complaints; To develop, provide, and improve the Site, including to better tailor the features, performance, security and support of the Site, and for statistical and analytics purposes; In any other way we may describe when you provide the information; For fraud, loss, and other crime prevention purposes; To assist in the investigation of suspected illegal or wrongful activity, and to protect and defend our rights and property, or the rights or safety of third parties; To enforce our Terms of Use, this Privacy Notice, or agreements with third parties; To comply with laws, regulators, court orders, or other legal obligations, or pursuant to legal process; or. The effective date of these Terms is May 18, 2022. Fighting Counterfeit Drugs, New Safety - NextPoint Therapeutics, a Cambridge, Mass.-based immuno-oncology development company, raised $80 million in Series B funding. Personal Information does not include publicly available information, information that is de-identified, aggregated information, or any other information outside the scope of the California Consumer Privacy Act of 2018 (CCPA). If we become aware that an individual under 13 years has provided us with Personal Data without parental consent, we will take steps to remove the data as permitted by law. Provide sufficient information that allows us to reasonably verify you are the person about whom we collected personal information or an authorized representative. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. I am thrilled about Leaps by Bayer's investment in NextPoint Therapeutics, Inc., a company developing next-gen precision immuno-oncology therapies for patients Juergen Eckhardt auf LinkedIn: NextPoint Therapeutics Announces $80 Million Series B Financing co-led by We may use Personal Data for a variety of different purposes as set out in further detail below. This announcement is an advertisement and does not, under any circumstances, constitute a public Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. It is committed to developing tumor cellular immunotherapeutics through its own innovative technology platforms. Phone: Please note that Google has its own privacy policies which are independent from ours. The investment portfolio includes more than 50 companies. You are not required to provide all Personal Data identified in this Privacy Notice in order to use the Site; however, if you do not provide the Personal Data requested, we may be unable to provide some or all of the Site to you. Cancer Immunol Res. available on the website of the Luxembourg Stock Exchange (www.bourse.lu). Deforestation and Forest Degradation, Postion To protect your privacy and security, we may take steps to verify your identity in order to respond to your request. Position, Position This can include cookies, web beacons and similar technologies as described above. Please note that if you are visiting the Site from outside of the United States, your information may be transferred to, stored, and/or processed in the US. Prospectus Directive), as permitted under the Prospectus Directive, or. 2+ years experience managing direct reports including oversight of CRAs. Phone: +49 214 30 1, Mllerstrae 178 This time around, we note that NextPoint Therapeutics hired Leena Gandhi as chief medical officer. Order 2005 (the Order) or (ii) high net worth companies, and other persons to whom it may lawfully accepted by any such use, means, instrumentality or facility or from within the United States. Dr. Zang is professor of microbiology & immunology, of medicine, . I am currently pursuing a M.Sc. focus on the areas of health care and nutrition. for a hungry planet, Bayer Learn more about Bayer and the opportunities available. Management, Code of Conduct I understand that it may affect my rights. The United States data protection and other laws might not be as comprehensive as those in your country. To learn more, visit nextpointtx.com. Both programs of the Boston-based company use the recently . (DE), Bayer interstate or foreign commerce, or of any facility of a national securities exchange of the United NextPoint reserves the right at all times to disclose information it deems necessary to satisfy any applicable law, regulation, legal process or governmental request, consistent with our. prohibited or restricted. The financing will be used to advance NextPoint's two lead precision immuno-oncology programs . NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. About. We are currently looking to add an Associate Director or Director, Clinical Operations to our fast moving, roll-up your sleeves team environment. NextPoint Therapeutics, a provider of precision immuno-oncology, has raised raised $80 million in Series B financing. Supply Chain Management Trainee Program, International Disseminate materials that impact or invade the privacy of others, such as photographs, video clips, sound recordings, personally identifiable information, or other materials that reveal personal, private or sensitive information about another person, without that persons consent. New Talent, Bayer 04 Headquarters, Dominican One of the candidates, lademirsen, is in a phase 2 trial for the treatment of Alport Syndrome. 616 followers 500+ connections. Press release content from Business Wire. offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in the world. sufficient information on the terms of the offer and any securities to be offered so as to enable an Similar to PD-L1, the tumor antigen HHLA2 is a member of the B7 receptor family1, is highly expressed on certain hard-to-treat cancers2, and drives avoidance of detection from the immune system. Scientists, At About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. NEXTPOINT EXPRESSLY DISCLAIMS: (i) ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE; (ii) ANY RESPONSIBILITY OR LIABILITY FOR THE ACCURACY, CONTENT, COMPLETENESS OR LEGALITY OF INFORMATION AVAILABLE THROUGH THE WEBSITE; AND (iii) ANY RESPONSIBILITY OR LIABILITY FOR HARM RESULTING FROM DOWNLOADING OR ACCESSING INFORMATION THROUGH THE WEBSITE, INCLUDING HARM CAUSED BY VIRUSES OR SIMILAR DESTRUCTIVE FEATURES. State by any measure implementing the Prospectus Directive in that Relevant Member State, and the Report, Quarterly This announcement does not contain or constitute an offer of, or the solicitation of an offer to Forward-Looking StatementsThis release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. Salvador, Hong jurisdiction. Phone: Briggs Morrison, MD, will step down as Interim CMO, but will continue to advise the company on an ongoing basis., I look forward to working with the NextPoint team to accelerate the development of programs targeting the HHLA2 pathway, a novel tumor-suppressive mechanism with the potential to impact many patients, commented Dr. Gandhi. transaction not subject to, the registration requirements of the Securities Act. Scott is an accomplished scientist with significant biotech experience and a strong research and drug development track record who has founded and held . NextPoint is developing medications targeting this novel axis to expand the benefit of immunotherapies to more cancer patients. The investment portfolio includes more than 50 companies. 5. securities in any Relevant Member State means the communication in any form and by any means of investment decision regarding the securities referred to herein should only be made on the basis Only you or a person registered with the California Secretary of State that you authorize to act on your behalf, may make a verifiable consumer request related to your personal information. About BayerBayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Audit, International solicitation of an offer to buy securities issued by Bayer. Archive, Events Announcements, Sustainability & In other jurisdictions, only certain categories of person may be allowed to view such NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells 13353 Berlin Publications, Job This announcement is an advertisement and does not, under any our employees, International If you would like to stop receiving newsletters or other marketing or promotional messages, notifications, or updates, you may do so by following the unsubscribe instructions that appear in these e-mail communications. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Sci Immunol. Japan or in any other jurisdiction in which such offer or solicitation is not authorized or to any | Learn more about Anne Koehler, PhD's . NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. Wei Y, Ren X, Galbo PM Jr, et al. Meeting & Agenda, Stockholders' Procurement Management Trainee Program, Bridging NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. +49 30 468 1111, Alfred-Nobel-Str. Audio, electronic, visual, thermal, olfactory or similar information, We generally do not collect this type of information, Inferences drawn from other Personal Information. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Community, Bayer NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine.